CXCR5 and rheumatoid arthritis: These studies together with results of the present work suggest that targeting CXCR5 would be an ideal candidate for the treatment of RA for several reasons: i) genetic deficiency for Cxcr5 completely prevents CIA, a well-established model of RA sharing several immunological patho-mechanisms and genetic susceptibility features with human RA.